Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) EBIT (2022 - 2025)

Cannabis Bioscience International Holdings' EBIT history spans 3 years, with the latest figure at -$95877.0 for Q4 2025.

  • For Q4 2025, EBIT fell 60.79% year-over-year to -$95877.0; the TTM value through Nov 2025 reached -$434795.0, down 15.89%, while the annual FY2025 figure was -$421365.0, 13.32% up from the prior year.
  • EBIT for Q4 2025 was -$95877.0 at Cannabis Bioscience International Holdings, down from -$74784.0 in the prior quarter.
  • Across five years, EBIT topped out at -$29634.0 in Q2 2024 and bottomed at -$284868.0 in Q1 2023.
  • The 3-year median for EBIT is -$113419.0 (2024), against an average of -$136494.3.
  • The largest annual shift saw EBIT surged 89.22% in 2024 before it crashed 355.22% in 2025.
  • A 3-year view of EBIT shows it stood at -$91398.0 in 2023, then soared by 34.76% to -$59627.0 in 2024, then tumbled by 60.79% to -$95877.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIH's EBIT are -$95877.0 (Q4 2025), -$74784.0 (Q3 2025), and -$134900.0 (Q2 2025).